CTOs on the Move

Ikena Oncology

www.ikenaoncology.com

 
Ikena Oncology is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

J. Craig Venter Institute (JVCI)

J. Craig Venter Institute (JVCI) is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advanced Biotech

Advanced Biotech is a Cobourg, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

A W Research Laboratories

A W Research Laboratories is a Brainerd, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Qiagen

QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics).

Sherlock Biosciences

Sherlock Biosciences aims to disrupt molecular diagnostics with better, faster, affordable tests. With our unique Engineering Biology platforms, we are on the cusp of solving challenges ranging from faster pathogen detection and simpler testing for cancer to improved food safety. We envision a world where our products will enable users to make more effective decisions in any environment, whether in hospitals, industrial settings, the developing world, or at home. Our team and founders include Engineering Biology pioneers with world-leading expertise in CRISPR and Synthetic Biology, diagnostic industry veterans, and disease-area authorities. Together, they provide an unparalleled set of capabilities that are transforming molecular diagnostics in clinical and non-clinical settings.